Hemophilia and Rare Bleeding Disorders » Hemophilia - Basic

Abstract Number: OC 37.4

A humanized mouse model to assess the therapeutic potential of IdeS in hemophilia A with inhibitors

M. Bou Jaoudeh¹, V. Daventure², S. Delignat², J. astermark³, H. Lévesque⁴, V. Proulle⁵, S. Lacroix-Desmazes⁶

Abstract Number: PB0174

Activated Factor XI as Activator of Thrombin Generation to Increase Assay Sensitivity

R. Arisz¹, T. van Lienden², R. de Laat-Kremers³, J. Eikenboom⁴, S. Schols⁵, M. de Maat⁶

Abstract Number: VPB0204

Association between platelet receptor genotypes and the bleeding tendency of hemophilia patients

L. Bury¹, H. Kuchi Bhotla², G. Piroli², E. Cesari², E. Falcinelli², G. Guglielmini², R. De Cristofaro³, B. Zieger⁴, P. Gresele²

Abstract Number: PB0181

Bleeding according to FVIII activity in 641 children with non-severe haemophilia – data from the PedNet study group

M. de Kovel¹, C. Königs², S. Ranta³, C. Escuriola Ettingshausen⁴, K. Fischer⁵

Abstract Number: OC 70.5

Bleeding in non-severe haemophilia A and B – data from the PedNet study group.

M. de Kovel¹, C. Königs², S. Ranta³, C. Escuriola Ettingshausen⁴, K. Fischer⁵

Abstract Number: PB0192

Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan

A. Amirah¹, I. Palau², A. Rosli¹, N. Allie²

Abstract Number: PB0199

Budget impact of increasing rVIII-SingleChain use in patients in Italy with moderate and severe hemophilia A

S. Yan¹, R. Tomic², M. Panebianco², E. Dlotko³, L. Stern³, R. Marino⁴

Abstract Number: VPB0206

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

N. Matsumoto¹, H. Abe¹, R. Kawasaki¹, Y. Tashiro¹, M. Noguchi¹, S. Harada¹, K. Yoneyama², T. Niino², T. Soeda¹, Y. Yoshimura¹

Abstract Number: VPB0208

Coagulant potential of emicizumab in child hemophilia A patients

M. Takeyama¹, N. Matsumoto², H. Abe², S. Harada², K. Ogiwara³, S. Furukawa³, T. Soeda², K. Nogami¹

Abstract Number: PB0177

Detection of IgG4 anti-FVIII levels as complementary test to define the ITI outcome in patients with hemophilia A: results from the BrazIT Study

D. Chaves¹, B. Ayala², R. Camelo³, L. Etto⁴, A. De Oliveira⁵, V. Franco⁶, M. Roberti⁷, R. Ribeiro⁸, M. De Cerqueira⁹, F. Callado¹⁰, T. Anegawa¹¹, M. Cerqueira¹², S. Rezende²

Abstract Number: OC 50.4

Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice

T. SEFIANE¹, V. Muczynski², X. Heiligenstein³, O. Christophe², C. Denis², C. Casari⁴, P. Lenting²

Abstract Number: PB0191

DNA extracellular traps as potential biomarker of chronic haemophilic synovitis and therapeutic perspective in patients treated with PRP

P. Oneto¹, M. Landro², C. Daffunchio², A. Douglas Price³, E. Carrera SIlva¹, H. Caviglia², J. Etulain⁴

Abstract Number: PB0193

Dose optimization for prophylaxis using a pharmacokinetic model for factor IX products in severe hemophilia B

B. Vandewalle¹, G. Castaman², M. Alvarez-Román³, C. Escuriola Ettingshausen⁴, L. Nemes⁵, R. Tomic⁶, P. Martins¹, J. Rodrigues⁷, K. Pinachyan⁸

Abstract Number: OC 30.2

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Real-life-data documented by eDiary smart medication

W. Mondorf¹, E. Hermann², C. Escuriola Ettingshausen³, F. Ronald⁴, K. Holstein⁵, R. Klamroth⁶, U. Sachs⁷

Abstract Number: PB0179

Establishment of a monolayer-based LSEC-like endothelial cell in vitro system from induced pluripotent stem cells

P. Chawla¹, M. Rath², J. Oldenburg³, H. Singer⁴

Abstract Number: PB0185

Exploring red blood cells as a novel tolerogenic approach for factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

M. Miranda¹, E. Brandsma², P. Kaijen¹, F. van Alphen³, R. van Bruggen⁴, K. Fijnvandraat⁵, S. Lacroix-Desmazes⁶, J. Voorberg¹

Abstract Number: OC 07.4

Exploring the conformational landscape of Factor VIII B domain in order to generate an all atom full length structure of the coagulation Factor VIII protein

S. Ramaraje Urs¹, S. Singh², H. Javed³, D. Fenel⁴, J. Teulon⁵, G. Schoehn⁵, J. Pellequer⁵, B. Ma⁶, D. Ugurlar⁶, D. Imhof⁷, J. Oldenburg⁸, A. Biswas¹

Abstract Number: VPB0207

Factor VIII K1813A has high affinity for activated factor IX and enhances global coagulation function

Y. Nakajima¹, M. Takeyama², A. Oda³, K. Nogami²

Abstract Number: PB0187

FIX binding to collagen IV generates thrombin via the extrinsic tenase

G. Morrow¹, M. Laffan², N. Curry³

Abstract Number: OC 37.2

Follicular regulatory T cells promote anti-FVIII inhibitor development in hemophilia A mice

W. Jing¹, J. Chen¹, Y. Cai¹, J. Schroeder¹, A. Dent², Q. Shi¹